This past summer, the Canadian Hemophilia Society (CHS) conducted an on-line survey on attitudes to and knowledge about gene therapy. The results were presented and...
Héma-Québec announced on November 30, following its Request for Proposals for recombinant factor VIII concentrates, that it had selected Esperoct. Esperoct is approved by Health...
Last August, the European Medicines Agency (EMA) granted conditional marketing authorization to BioMarin’s Roctavian (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A...
Montreal – November 28, 2022 – The U.S. Food and Drug Administration (FDA) approved the first gene therapy for hemophilia B on November 22. Etranacogene...
Each year the CHS honours individuals who have made a significant contribution to improving the quality of life of people with bleeding disorders. The 2023...
